By IDSE News Staff
ViiV Healthcare with the Medicines Patent Pool (MPP) signed sublicense agreements with Aurobindo, Cipla and Viatris—through its subsidiary Mylan—to manufacture generic versions of cabotegravir long-acting (CAB-LA; Apretude) for HIV pre-exposure prophylaxis (PrEP). This action is enabled by the signing of a voluntary licensing agreement for patents related to CAB-LA for PrEP with MPP in July 2022.
Only seven months after the first regulatory approval of CAB-LA for